StockData

Delcath Systems vs Kestra Medical Technologies

DCTH and KMTS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How DCTH and KMTS compare

Kestra Medical Technologies is the larger company, worth 2.5 times as much as Delcath Systems ($1.7B against $672M).

Kestra Medical Technologies grew revenue faster over the last twelve months (60.7% versus 35.8% for Delcath Systems).

Delcath Systems keeps more of each dollar of sales as profit, with a net margin of 0.56% compared with −140% at Kestra Medical Technologies.

Delcath Systems scores higher on the StockData Score (13 against 5 for Kestra Medical Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricDCTHKMTS
Size and price
Market cap$672M$1.7B
Share price$19.37$28.27
Change, 1 year117%13.0%
Change, 5 years98.9%–
Beta (5Y)1.981.25
Employees156443
StockData Score
Total score13 (better)5
Valuation score00
Growth score4 (better)3
Performance score3 (better)0
Health score6 (better)2
Dividend score00
Valuation
P/E1937×–
P/S7.0× (better)15.8×
P/B5.5×–
P/FCF38.4×–
FCF yield2.6% (better)−7.3%
Growth
Revenue growth (TTM)35.8%60.7% (better)
Net income growth (TTM)−76.2%–
EPS growth (TTM)−80.0%–
Profitability
Gross margin87.1% (better)53.9%
Operating margin−1.9% (better)−134%
Net margin0.56% (better)−140%
FCF margin18.3% (better)−115%
Return on equity0.47%–
Return on invested capital−3.7%–
Financial health
Debt / equity0.00–
Interest coverage–−19.0×
Current ratio9.83 (better)4.69
Altman Z-score21.70 (better)4.84
Piotroski F-score7 (better)4
Dividends and buybacks
Buyback yield−0.09%–
Shareholder yield−0.09%0.00% (better)
Ownership
Held by institutions50.2%98.6%
Held by insiders37.4%44.0%
Insider net buying, 12 months−$338K (better)−$15.3M
Short interest, % of float8.2%12.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.